Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Blog
Key Changes to Health Technology Assessments (HTAs) in the UK
The National Institute for Health and Care Excellence (NICE) will mark the start of 2022 by implementing changes to health technology assessments (HTAs), demonstrating adaptability of regulatory bodies as medical technologies continue to evolve. The final HTA changes aim to provide...
Blog
Bypassing NICE: Manufacturers are Looking Towards NHS England to Support Early Access
There has been a trend in manufacturers opting to bypass the NICE appraisal process and have struck deals with NHS England directly to support market access for their novel therapies.
Blog
Global Evidence Requirements to Launch a Digital Health Technology
In this article, Trinity analyzed existing guidelines and evaluation frameworks for digital health technologies, including mobile health (mHealth) applications, to identify key evidence requirements and areas that should be considered in the clinical assessment of digital health services.
Blog
Are Current Reimbursement Options for Opioid Use Disorder DTx Causing a Barrier to Widespread Adoption in the USA?
In 2020, Trinity assessed three applications developed to treat Opioid Use Disorders (OUD) (e.g., reSET-O, Connections, DynamiCare) through the lens of ICER conducting a cost-effectiveness evaluation. Only a year later, several more health tech startups have adopted a preventative outlook and seek...
Blog
Insulin Approval Pathways USA vs. EU
Executive Summary Trinity’s Take: All types of insulin products included in this analysis had significantly higher list prices in the USA vs. DEU, GBR, and FRA despite the availability of often equivalent products, brands, and technologies. While the only biosimilar...
Blog
Cell and Gene Therapy Landscape: Challenges and Opportunities for Biotech and Investors
Executive Summary The American Society of Cell & Gene Therapy (ASCGT) wrapped up their 2021 conference earlier this year, which covered a range of topics, from new scientific advances to the evolving pricing and market access dynamics surrounding cell and...
